Eric Lagasse News Today

Dr. Michael Hufford, CEO of LyGenesis, believes in leveraging natural biology to develop cell therapies. Learn how the company’s doing so to...

With donor livers perpetually in short supply, growing them may be the answer.

Donor livers are in short supply for transplants. A startup is attempting to grow new ones in people instead.

The first human trial is underway and could transform organ donation if successful.

A new treatment that could turn a single donor liver into “mini livers” capable of saving 75 or more lives is heading into human trials.

ITolerance and LyGenesis announce a joint research collaboration to regrow functioning ectopic livers without the need for immune suppression.

The University of Pittsburgh Office of Innovation and Entrepreneurship presented its 2022 Celebration of Innovation on April 21. The event recognizes the achievements of Pitt faculty and student innovators who are seeking to improve people’s lives through the commercialization of their ideas and discoveries. In addition to recognizing all faculty and students who submitted an

/PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end...

Experts in the field of longevity believe that this life-changing goal might be within our reach.